A best-in-class, asset-light royalty “biotech utility” powering the global shift from IV to subcutaneous biologics—while racing to extend its moat beyond the 2027/2029 patent cliff with Wave 3 hyperconcentration tech.
Overview
Halozyme Therapeutics (HALO) is a leading drug-delivery platform company built around its proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) and the ENHANZE technology that enables subcutaneous delivery of medicines historically limited to IV infusion. By temporarily degrading hyaluronan in subcutaneous tissue, ENHANZE allows rapid absorption of large-volume/viscous formulations, reducing infusion times from hours to minutes and improving patient/provider burden—an increasingly valuable proposition across oncology, immunology, and other biologics-heavy categories. Halozyme’s business model is high-margin and asset-light, monetized through (1) recurring partner royalties (the highest-quality stream), (2) product sales (including bulk rHuPH20 API sold to partners and select proprietary products like Hylenex and XYOSTED), and (3) collaboration and milestone payments tied to partner progress/new licenses. In preliminary FY2025 results, total revenue was $1.385–$1.400B, with royalties $865–$870M (51%–52% YoY growth) driven by the “Blockbuster Trio” of Darzalex SC (J&J/Janssen), Phesgo (Roche), and Vyvgart Hytrulo (argenx). Product sales contributed ~$372–$377M and collaboration/milestones ~$148–$153M. Strategically, Halozyme expanded in late 2025 with Elektrofi and Surf Bio acquisitions, adding hyperconcentration and polymer stabilization technologies intended to broaden SC delivery to more biologics (including highly concentrated doses) and extend the IP moat into the mid-2040s—an important counterbalance to the 2027/2029 expiration of the original ENHANZE composition patents.